Gilead Sciences, Inc.

A high-profile expert panel that included renown clinician-scientist and Director of the Cancer Science Institute of Singapore, Prof Ashok Venkitaraman, discussed some of the pressing global public he

Gilead Sciences’ TROP2-directed antibody-drug conjugate Trodelvy (sacituzumab govitecan-hziy) has a strong chance of cornering most of the market for first-line advanced or metastatic triple-negative

The US Food and Drug Administration’s June user fee goal calendar reflects the gravitational pull of major meetings. The month opens with the monster American Society of Clinical Oncology annual meeti

Therapies ranging from small molecules to immuno-oncology drugs will make appearances at the 2025 American Society of Clinical Oncology meeting. These include drugs that are seen as having the potenti